Dyne Therapeutics
The Senior TMF Specialist ensures the integrity, completeness, and compliance of the Trial Master File (TMF) across clinical studies. This role is responsible for maintaining, managing, and inspecting TMF documentation in accordance with regulatory standards and company procedures.
Headquarters
Waltham, Massachusetts, United States
Company Size
51-200 employees
Founded
2018
Dyne Therapeutics is a biotechnology company developing nucleic acid–based therapies for genetically driven neuromuscular diseases. Leveraging its proprietary FORCE™ platform, Dyne aims to address the root cause of disease and deliver functional improvement for people living with conditions such as Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1), and facioscapulohumeral muscular dystrophy (FSHD). The company advances a pipeline of therapeutics from discovery through clinical development with the mission of transforming the lives of patients with rare neuromuscular diseases.
Dyne Therapeutics: Strong DELIVER Data Strengthens The Bull Case (NASDAQ:DYN)
2 days ago
Dyne Therapeutics Announces New Positive Cardiopulmonary Results from DELIVER Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD)
3 days ago
Dyne Therapeutics (DYN) Q4 Loss Narrows to $0.73/Share vs $0.76 Estimate, Shares Surge 11.8%
22 hours ago
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Dyne Therapeutics.
Dyne Therapeutics didn’t post a salary, so this is our estimate from similar listings.
150-patient Dyne trial focuses on myotonic dystrophy daily function
3 days ago